Status:
COMPLETED
Faslodex International Observational Non-Interventional Study in Advanced Breast Cancer (BC)
Lead Sponsor:
AstraZeneca
Conditions:
Breast Cancer
Eligibility:
FEMALE
Brief Summary
The purpose is to collect real life data on the use of fulvestrant in normal clinical practice in Austria and document the clinical benefit of fulvestrant treatment.
Eligibility Criteria
Inclusion
- Postmenopausal women with hormone receptor-positive locally advanced or metastatic breast cancer
- Ability to read and write and complete questionnaires
- Provision of written informed consent
- Patients who already received a prescription for fulvestrant
Exclusion
- A subject who does not fulfil all the above mentioned inclusion criteria is not allowed to participate in this NIS
Key Trial Info
Start Date :
April 1 2009
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 1 2010
Estimated Enrollment :
57 Patients enrolled
Trial Details
Trial ID
NCT00880711
Start Date
April 1 2009
End Date
December 1 2010
Last Update
November 30 2011
Active Locations (13)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Graz, Austria
2
Research Site
Innsbruck, Austria
3
Research Site
Klagenfurt, Austria
4
Research Site
Leoben, Austria